Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study (original) (raw)

References

  1. Rajkumar SV, Blood E, Vesole DH, Fonseca R, Greipp PR . Phase iii clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436.
    Article CAS PubMed Google Scholar
  2. Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319–4323.
    Article CAS PubMed Google Scholar
  3. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106: 4050–4053.
    Article CAS PubMed PubMed Central Google Scholar
  4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.
    Article CAS PubMed Google Scholar
  5. Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol 2009; 27: 5008–5014.
    Article CAS PubMed Google Scholar
  6. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007; 357: 2133–2142.
    Article CAS PubMed Google Scholar
  7. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007; 357: 2123–2132.
    Article CAS PubMed Google Scholar
  8. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29–37.
    Article CAS PubMed Google Scholar
  9. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.
    Article CAS PubMed PubMed Central Google Scholar
  10. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.
    CAS PubMed Google Scholar
  11. Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O et al. Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res 2009; 15: 5250–5257.
    Article CAS PubMed PubMed Central Google Scholar
  12. Kumar SK, Mikhael JR, Buadi FK, Dingli D, Dispenzieri A, Fonseca R et al. Management of newly diagnosed symptomatic multiple myeloma: updated mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009; 84: 1095–1110.
    Article CAS PubMed PubMed Central Google Scholar
  13. Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867–874.
    Article CAS PubMed Google Scholar
  14. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609–2617.
    Article CAS PubMed Google Scholar
  15. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565–1571.
    Article CAS PubMed Google Scholar
  16. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P . Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231–239.
    Article CAS PubMed Google Scholar
  17. Davis S, Wright PW, Schulman SF, Hill LD, Pinkham RD, Johnson LP et al. Participants in prospective, randomized clinical trials for resected non-small cell lung cancer have improved survival compared with nonparticipants in such trials. Cancer 1985; 56: 1710–1718.
    Article CAS PubMed Google Scholar
  18. Karjalainen S, Palva I . Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland. BMJ 1989; 299: 1069–1072.
    Article CAS PubMed PubMed Central Google Scholar
  19. Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.
    Article CAS PubMed Google Scholar
  20. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
    Article CAS PubMed Google Scholar
  21. Kumar S, Lacy MQ, Dispenzieri A, Buadi F, Hayman SR, Dingli D et al. Novel Agents for Initial Therapy of Multiple Myeloma: Comparable Results with Continued Initial Therapy and Delayed Transplantation at Relapse Versus Early Transplantation. ASH Ann Meet Abstr 2009; 114: 956.
    Google Scholar
  22. Sood R, Carloss H, Kerr R, Lopez J, Lee M, Druck M et al. Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib. Am J Hematol 2009; 84: 657–660.
    Article CAS PubMed Google Scholar
  23. Conner TM, Doan QD, Walters IB, LeBlanc AL, Beveridge RA . An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma. Clin Lymph Myeloma 2008; 8: 140–145.
    Article CAS Google Scholar
  24. Warzocha K, Kraj M, Poglod R, Kwasniak B . Bortezomib in multiple myeloma: treatment and retreatment. A single center experience. Acta Pol Pharm 2008; 65: 753–756.
    CAS PubMed Google Scholar
  25. Wolf J, Richardson PG, Schuster M, LeBlanc A, Walters IB, Battleman DS . Utility of bortezomib retreatment in relapsed or refractory multiple myeloma patients: a multicenter case series. Clin Adv Hematol Oncol 2008; 6: 755–760.
    PubMed Google Scholar
  26. Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J Clin Oncol 1998; 16: 3832–3842.
    Article Google Scholar
  27. Gertz MA, Kumar S, Lacy MQ, Dispenzieri A, Dingli D, Hayman SR et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 2010; 115: 2348–2353.
    Article CAS PubMed Google Scholar
  28. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412–3420.
    Article PubMed Google Scholar
  29. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210–2221.
    Article CAS PubMed PubMed Central Google Scholar
  30. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.
    Article CAS PubMed Google Scholar
  31. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489–3495.
    Article CAS PubMed Google Scholar

Download references

Author information

Author notes

  1. See Appendix

Authors and Affiliations

  1. Divison of Hematology, Mayo Clinic, Rochester, MN, USA
    S K Kumar & S V Rajkumar
  2. Division of Hemato-Oncology, Gachon University Gil Hospital, Incheon, Republic of Korea
    J H Lee
  3. Department of Hematology, Hospital Universitario 12 de Octubre, Madrid, Spain
    J J Lahuerta
  4. Department of Hematology, Royal Marsden Hospital, Sutton, UK
    G Morgan
  5. Department of Medical Oncology, Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA
    P G Richardson & J Feather
  6. Cancer Research & Biostatistics, Seattle, WA, USA
    J Crowley, J Haessler & A Hoering
  7. Division of Hematology, University Hospital Hotel-Dieu, Nantes, France
    P Moreau
  8. Service du Maladies du Sang, Hopital Claude Huriez, CHU, Lille, France
    X LeLeu
  9. Service D’hématologie CHU, Nancy, France
    C Hulin
  10. Department of Hematology, Erasmus MC, Rotterdam, The Netherlands
    S K Klein & P Sonneveld
  11. Medical Oncology, Hackensack University Medical Center, The Cancer Center, Hackensack, NJ, USA
    D Siegel
  12. Hematology, Hospital Clinic, Barcelona, Spain
    J Bladé
  13. Hematology, University of Heidelberg, Heidelberg, Germany
    H Goldschmidt
  14. Medical Oncology, Mt. Sinai Cancer Institute, New York, NY, USA
    S Jagannath
  15. Servico de Hematologia, Hospital Universario de Salamanca, Salamanca, Spain
    J S Miguel
  16. University of Texas/MD Anderson Cancer Center, Houston, TX, USA
    R Orlowski
  17. Department of Hematology, University of Torino, Torino, Italy
    A Palumbo
  18. Department of Hematology, University of Hamburg, Hamburg, Germany
    O Sezer
  19. Cedars-Sinai Outpatient Cancer Center at the Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
    B G M Durie

Authors

  1. S K Kumar
  2. J H Lee
  3. J J Lahuerta
  4. G Morgan
  5. P G Richardson
  6. J Crowley
  7. J Haessler
  8. J Feather
  9. A Hoering
  10. P Moreau
  11. X LeLeu
  12. C Hulin
  13. S K Klein
  14. P Sonneveld
  15. D Siegel
  16. J Bladé
  17. H Goldschmidt
  18. S Jagannath
  19. J S Miguel
  20. R Orlowski
  21. A Palumbo
  22. O Sezer
  23. S V Rajkumar
  24. B G M Durie

Consortia

on behalf of the International Myeloma Working Group

International Myeloma Working Group

Corresponding author

Correspondence toS K Kumar.

Ethics declarations

Competing interests

JJL is on the Scientific advisory boards of Celgene and Janssen-Cilag. PGR and JSM are Advisory board participants for Celgene, Millenium, Johnson and Johnson. DS is on the Speakers Bureau and BD is an Advisory board participant for Celgene and Millenium. AP is an Advisory Board participant for Celgene, Johnson and Johnson. JB has received Honoraria for lectures and advisory boards from Celgene, Jansen Cilag and Grant support from Celgene and Jansen-Cilag. The remaining authors declare no conflict of interest.

Additional information

Niels Abildgaard, Syddansk Universitet, Odense, Denmark Rafat Abonour, Indiana University School of Medicine, Indianapolis, Indiana, USA Ray Alexanian, MD Anderson, Houston, Texas, USA Melissa Alsina, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA Kenneth C. Anderson, DFCI, Boston, Massachusetts, USA Michael Attal, Purpan Hospital, Toulouse, France Hervé Avet-Loiseau, Institute de Biologie, Nantes, France Ashraf Badros, University of Maryland, Baltimore, Maryland, USA Dalsu Baris, National Cancer Institute, Bethesda, Maryland, USA Bart Barlogie, M.I.R.T. UAMS Little Rock, Arkanas, USA Régis Bataille, Institute de Biologie, Nantes, France Meral Beksaç, Ankara University, Ankara, Turkey Andrew Belch, Cross Cancer Institute, Alberta, Canada Dina Ben-Yehuda, Hadassah University Hospital, Hadassah, Israel Bill Bensinger, Fred Hutchinson Cancer Center, Seattle, Washington, USA P. Leif Bergsagel, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA Jenny Bird, Bristol Haematology and Oncology Center, Bristol, UK Joan Bladé, Hospital Clinica, Barcelona, Spain Mario Boccadoro, University of Torino, Torino, Italy Michele Cavo, Universita di Bologna, Bologna, Italy Asher Chanan-Khan, Roswell Park Cancer Institute, Buffalo, New York USA Wen Ming Chen, MM Research Center of Beijing, Beijing, China Tony Child, Leeds General Hospital, Leeds, United Kingdom James Chim, Department of Medicine, Queen Mary Hospital, Hong Kong Wee-Joo Chng, National University Health System, Singapore Ray Comenzo, Tufts Medical School, Boston, Massachusetts, USA John Crowley, Cancer Research and Biostatistics, Seattle, Washington, USA William Dalton, H. Lee Moffitt, Tampa, Florida, USA Faith Davies, Royal Marsden Hospital, London, England Cármino de Souza, Univeridade de Campinas, Caminas, Brazil Michel Delforge, University Hospital Gasthuisberg, Leuven, Belgium Meletios Dimopoulos, University of Athens School of Medicine, Athens, Greece Angela Dispenzieri, Mayo Clinic, Rochester, Minnesota, USA Johannes Drach, University of Vienna, Vienna, Austria Matthew Drake, Mayo Clinic Rochester, Rochester, Minnesota, USA Brian G.M. Durie, Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, California, USA Hermann Einsele, Universitätsklinik Würzburg, Würzburg, Germany Theirry Facon, Centre Hospitalier Regional Universitaire de Lille, Lille, France Dorotea Fantl, Socieded Argentinade Hematolgia, Buenos Aires, Argentina Jean-Paul Fermand, Hopitaux de Paris, Paris, France Rafael Fonseca, Mayo Clinic Arizona, Scottsdale, Arizona, USA Gösta Gahrton, Karolinska Institute for Medicine, Huddinge, Sweden Ramón García-Sanz, University Hospital of Salamanca, Salamanca, Spain Christina Gasparetto, Duke University Medical Center, Durham, North Carolina, USA Morie Gertz, Mayo Clinic, Rochester, Minnesota, USA John Gibson, Royal Prince Alfred Hospital, Sydney, Australia Sergio Giralt, MD Anderson Cancer Center, Houston, Texas, USA Hartmut Goldschmidt, University Hospital Heidelberg, Heidelberg, Germany Philip Greipp, Mayo Clinic, Rochester, Minnesota, USA Roman Hajek, Brno University, Brno, Czech Republic Izhar Hardan, Tel Aviv University, Tel Aviv, Israel Parameswaran Hari, Medical College of Wisconsin, Milwaukee, Wisconsin, USA Jean-Luc Harousseau, Institute de Biologie, Nantes, France Hiroyuki Hata, Kumamoto University Hospital, Kumamoto, Japan Yutaka Hattori, Keio University School of Medicine, Tokyo, Japan Tom Heffner, Emory University, Atlanta, Georgia, USA Joy Ho, Royal Prince Alfred Hospital, Sydney, Australia Vania Hungria, Clinica San Germano, Sao Paolo, Brazil Shinsuke Ida, Nagoya City University Medical School, Nagoya, Japan Peter Jacobs, Constantiaberg Medi-Clinic, Plumstead, South Africa Sundar Jagannath, Mt. Sinai Cancer Institute, New York, New York, USA Hans E Johnsen, AHSIC Aarhus University, Aalbor, Denmark Hou Jian, Shanghai Chang Zheng Hospital, Shanghai, China Douglas Joshua, Royal Prince Alfred Hospital, Sydney, Australia Artur Jurczyszyn, The Myeloma Treatment Foundation, Poland Michio Kawano, Yamaguchi University, Ube, Japan Nicolaus Kröger, University Hospital Hamburg, Hamburg, Germany Shaji Kumar, Department of Hematology, Mayo Clinic, Minnesota, USA Robert A. Kyle, Department of Laboratory Med. and Pathology, Mayo Clinic, Minnesota, USA Martha Lacy, Mayo Clinic Rochester, Rochester, Minnesota, USA Juan José Lahuerta, Grupo Español di Mieloma, Hospital Universitario 12 de Octubre, Madrid, Spain Ola Landgren, National Cancer Institute, Bethesda, Maryland, USA Jacob Laubach, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Jae Hoon Lee, Gachon University Gil Hospital, Incheon, Korea Xavier LeLeu, Hospital Huriez, CHRU Lille, France Suzanne Lentzsch, University of Pittsburgh, Pittsburgh, Pennsylvania, USA Henk Lokhorst, University Medical CenterUtrecht, Utrecht, The Netherlands Sagar Lonial, Emory University Medical School, Atlanta, Georgia, USA Heinz Ludwig, Wilhelminenspital Der Stat Wien, Vienna, Austria Angelo Maiolino, Rua fonte da Saudade, Rio de Janeiro, Brazil María Mateos, University of Salamanca, Salamanca, Spain Jayesh Mehta, Northwestern University, Chicago, Illinois, USA Ulf-Henrik Mellqvist, Sahlgrenska University Hospital, Gothenburg, Sweden GiamPaolo Merlini, University of Pavia, Pavia, Italy Joseph Mikhael, Mayo Clinic Arizona, Scottsdale, Arizona, USA Angelina Rodríguez Morales, Bonco Metro Politano de Sangre, Caracas, Venezuela Philippe Moreau, University Hospital, Nantes, France Gareth Morgan, Royal Marsden Hospital, London, England Hareth Nari, Karolinska University Hospital, Stockholm, Sweden Nikhil Munshi, Diane Farber Cancer Institute, Boston, Massachusetts, USA Ruben Niesvizky, Weill Medical College of Cornell University, New York, New York, USA Amara Nouel, Hospital Rutz y Paez, Bolivar, Venezuela Yana Novis, Hospital SírioLibanês, Bela Vista, Brazil Robert Orlowski, MD Anderson Cancer Center, Houston, Texas, USA Antonio Palumbo, Cathedra Ematologia, Torino, Italy Santiago Pavlovsky, Fundaleu, Buenos Aires, Argentina Linda Pilarski, University of Alberta, Alberta, Canada Raymond Powles, Leukemia & Myeloma, Wimbledon, England Noopur Raje, Massachusetts General Hospital, Boston, Massachusetts, USA S. Vincent Rajkumar, Mayo Clinic, Rochester, Minnesota, USA Donna Reece, Princess Margaret Hospital, Toronto, Canada Tony Reiman, Cross Cancer Institute, Alberta, Canada Paul G. Richardson, Dana Farber Cancer Institute, Boston, Massachusetts, USA David Roodman, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania USA Laura Rosiñol, Hospital Clinic, Barcelona, Spain Jesús San Miguel, University of Salamanca, Salamanca, Spain Orhan Sezer, Universität Hamburg, Hamburg, Germany Jatin J. Shah, MD Anderson Cancer Institute, Houston, Texas, USA John Shaughnessy, M.I.R.T. UAMS, Little Rock, Arkansas, USA Kazuyuki Shimizu, Nagoya City Midori General Hospital, Nagoya, Japan Chaim Shustik, McGill University, Montreal, Canada David Siegel, Hackensack, Cancer Center, Hackensack, New Jersey, USA Seema Singhal, Northwestern University, Chicago, Illinois, USA Pieter Sonneveld, Erasmus MC, Rotterdam, The Netherlands Andrew Spencer, The Alfred Hospital, Melbourne, Australia Edward Stadtmauer, University of Pennsylvania, Philadelphia, Pennsylvania, USA Keith Stewart, Mayo Clinic Arizona, Scottsdale, Arizona, USA Evangelos Terpos, University of Athens School of Medicine, Athens, Greece Patrizia Tosi, Italian Cooperative Group, Istituto di Ematologia Seragnoli, Bologna, Italy Guido Tricot, Huntsman Cancer Institute, Salt Lake City, Utah, USA Ingemar Turesson, SKANE University Hospital, Malmo, Sweden Ben Van Camp, Vrije Universiteit Brussels, Brussels, Belgium Brian Van Ness, University of Minnesota, Minneapolis, Minnesota, USA Ivan Van Riet, Brussels Vrija University, Brussels, Belgium Isabelle Vande Broek, Vrije Universiteit Brussels, Brussels, Belgium Karin Vanderkerken, Vrije University Brussels VUB, Brussels, Belgium Robert Vescio, Cedars-Sinai Cancer Center, Los Angeles, California, USA David Vesole, Hackensack Cancer Center, Hackensack, New Jersey, USA Anders Waage, University Hospital, Trondheim, Norway NSMG Michael Wang, MD Anderson, Houston, Texas, USA Donna Weber, MD Anderson, Houston, Texas, USA Jan Westin, Sahlgrenska University Hospital, Gothenburg, Sweden Keith Wheatley, University of Birmingham, Birmingham, United Kingdom Jeffrey Zonder, Karmanos Cancer Institute, Detroit, Michigan, USA

Author’s contributions

All authors (except JC, JH, JF and AH) provided patient data and were involved in manuscript preparation. JC, JH, JF and AH were involved in the statistical analysis.

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

About this article

Cite this article

Kumar, S., Lee, J., Lahuerta, J. et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study.Leukemia 26, 149–157 (2012). https://doi.org/10.1038/leu.2011.196

Download citation

Keywords